Sigrid Therapeutics lists SiPore® portfolio on Fullscript platform
Sigrid Therapeutics has listed its SiPore® practitioner portfolio on Fullscript, a North American health technology platform serving more than 125,000 healthcare providers. The move gives US clinicians direct access to SiPore® Capsules and SiPore® Liquid through a platform they already use to source supplements and clinical decision tools.
SiPore® is positioned by the company as a gut-local, non-systemic approach to metabolic health. The technology is described as working by mechanically entrapping digestive enzymes during digestion, slowing the breakdown of carbohydrates and fats. Sigrid says the platform remains within the gastrointestinal tract and is not absorbed into the bloodstream, distinguishing it from systemic metabolic therapies.
The products and the clinical rationale
The practitioner portfolio comprises two formats. SiPore® Capsules are classified as a dietary supplement and are aimed at everyday metabolic support, with the company saying they are intended to support steadier post-meal glucose patterns. SiPore® Liquid is classified as a medical food, available in ready-to-consume sachets, and represents the highest-strength dose of the SiPore® platform, designed for structured metabolic health protocols.
Sigrid's chief executive, Claus Kjærsgaard, said that making the portfolio available on Fullscript would allow clinicians to "incorporate gut-local metabolic support into routine patient care" through a trusted channel. The company frames the launch against growing clinical interest in post-meal physiology, pointing to the wider adoption of continuous glucose monitoring and time-in-range metrics as drivers of demand for earlier metabolic intervention tools.
The Fullscript listing is accompanied by educational resources for practitioners, including mechanism of action materials, clinical science summaries and patient protocols.
Market context and evidence landscape
The gut-local metabolic health space sits at an intersection of the dietary supplement market and emerging medical nutrition categories, and is attracting attention partly as a counterpoint to the rapid growth of GLP-1 receptor agonists. Where GLP-1 drugs address metabolic dysfunction systemically, gut-local approaches target the digestive process directly, appealing to clinicians seeking earlier-stage or adjunctive interventions for patients not yet indicated for pharmacological therapy.
Sigrid reports that its pivotal SHINE clinical study has been accepted for publication in eClinicalMedicine, a peer-reviewed journal within The Lancet Discovery Science group. The company has not yet released the underlying trial data publicly; the acceptance of the manuscript for publication is a meaningful step, but readers should note that trial results have not been independently reviewed in this release and the full dataset is not yet in the public domain.
The Fullscript channel is well-suited to reaching integrative and functional medicine practitioners, who represent a core adopter group for nutritional and gut-health interventions. Fullscript says it supports more than five million patients annually across North America, giving Sigrid meaningful distribution reach without the overhead of a direct sales force.
Investors and clinicians following the metabolic health space will be watching for the full SHINE publication, which should provide the clearest signal yet of how SiPore® performs against clinical endpoints and how it compares with established dietary fibre and alpha-glucosidase inhibitor approaches in the gut-local category.